locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib). Enrollment in HARMONi was completed in the second-half of ...

The approval is based on the Phase 3 MARIPOSA study, which demonstrated that amivantamab plus lazertinib significantly reduced the risk of disease progression or death by 30% compared to osimertinib.

In our news wrap Wednesday, power in Puerto Rico has been restored after an island-wide outage struck on New Year's Eve, one person is dead after a Tesla truck caught fire and exploded outside a ...